Advertisement

Topics

Clinical Trials About "EXECU SUMMIT,LLC" RSS

15:18 EDT 22nd October 2018 | BioPortfolio

We list hundreds of Clinical Trials about "EXECU SUMMIT,LLC" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "EXECU SUMMIT,LLC" on BioPortfolio

We have published hundreds of EXECU SUMMIT,LLC news stories on BioPortfolio along with dozens of EXECU SUMMIT,LLC Clinical Trials and PubMed Articles about EXECU SUMMIT,LLC for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of EXECU SUMMIT,LLC Companies in our database. You can also find out about relevant EXECU SUMMIT,LLC Drugs and Medications on this site too.

Showing "EXECU SUMMIT" Clinical Trials, all 11

Relevant

Clinical Study Comparing Two Implant Surface Finishes in Patients Undergoing Cementless Total Hip Replacement

Prospective, randomized study of Summit Porocoat versus Summit DuoFix HA in total hip arthroplasty


Preventing Sexual Violence Through a Comprehensive, Peer-led Initiative

The purpose of this matched comparison, multiple baseline study is to evaluate the effectiveness of a comprehensive youth-led sexual violence (SV) prevention program, Youth Voices in Prevention (Youth VIP). The prevention program builds on youth-adult partnerships among middle and high school students in Rapid City, South Dakota. Consenting students will take part in a youth summit where they will be trained as popular opinion leaders to spread SV prevention messages among midd...

Probably Relevant

Acclimatization Mechanisms During Ascent to 7500m

The trial evaluates the role of ascent protocol on acute mountain sickness and cardio-respiratory physiology during an ascent to Muztagh Ata (7546m). Two groups of mountaineers ascend with different acclimatization time to the summit. The prevalence and severity of symptoms of acute mountain sickness are evaluated along with physiologic variables.


To Compare Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection

Summit is developing ridinilazole as a novel antimicrobial for Clostridium difficile Infection (CDI) with the goal of achieving comparable cure rates to standard of care, but reducing rates of recurrent disease. A phase 2 proof of concept study, with vancomycin as comparator, demonstrated these attributes with a comparable safety profile. A high fecal concentration of ridinilazole and little systemic exposure were noted. The rationale for this phase 3 study is to confir...

Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection

Summit is developing ridinilazole as a novel antimicrobial for Clostridium difficile Infection (CDI) with the goal of achieving comparable cure rates to standard of care, but reducing rates of recurrent disease. A phase 2 proof of concept study, with vancomycin as comparator, demonstrated these attributes with a comparable safety profile. A high fecal concentration of ridinilazole and little systemic exposure were noted. The rationale for this phase 3 study is to confir...

Sequential vs. Monophasic Media Impact Trial (SuMMIT)

To evaluate the impact of two FDA approved culture media on potential of human embryos resulting from IVF (sequential & monophasic media). Half of each patient's embryos will be randomly assigned to grow in monophasic media & the other half in sequential media. All embryos will undergo Comprehensive Chromosome Screening (CCS) & the best euploid embryo from each group will be transferred resulting in a double embryo transfer (DET). If there are only euploid embryos from one g...

Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma

The primary aim of this trial is to determine the effect of a short course (i.e., 3 cycles) of low-dose Bortezomib (Velcade) on bone remodeling and on disease progression. The dose of bortezomib used in this trial of 0.7 mg/m2 is the lowest dose which has shown efficacy in the 3 largest monotherapy trials with bortezomib. 17% of patients in the APEX, 9% patients in CREST and 24% in SUMMIT trials were treated with 0.7 mg/m2 dosages. Bortezomib will be given on days 1, 8, 15, 22 ...

NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma

A clinical trial with biweekly regimen of gemcitabine and nab-paclitaxel for Soft tissue sarcomas (STSs). A Promising antitumor activity in patients with metastatic STS has been reported with gemcitabine alone or in combination with taxanes including docetaxel and paclitaxel in pre-treated patients. Nab-paclitaxel is a 130-nm albumin-bound formulation of paclitaxel particles (Celgene, Summit, NJ) which was designed to eliminate the toxicities associated with Cremophor®...

Closed Loop Deep Brain Stimulation in Parkinson's Disease

This is an exploratory pilot study to test a variety of strategies for feedback-controlled deep brain stimulation. Twenty Parkinson's disease patients with motor fluctuations and will be implanted bilaterally with a totally internalized bidirectional neural interface, Medtronic Activa RC+S. Each RC+S will be attached to both quadripolar subthalamic DBS lead, and quadripolar subdural cortical paddle lead. Investigators will collect and characterize each subject's physiological b...

Streptococcal Infection and Respiratory Distress in Newborns

This study will evaluate whether babies are more at risk of developing breathing problems if their mothers carry group B streptococci (GBS) in vagina/rectum, and whether the breathing problem is due to phospholipids released by the GBS. About one in five pregnant women carry GBS in their vagina/rectum. Mothers who carry these bacteria are given antibiotics during labor to prevent infection in the baby. However, recently it has been suspected that even without blood stream inf...

Early Point-Of-Care Blood Tests, ECG & X-rays in the Emergency Department

The 2015 Abbott Point-of-Care Great Minds Summit in Berlin presented novel research that showed the potential for upfront, point-of-care (POC) blood testing to improve waiting times, costs and patient flow in the Emergency Department (ED). POC testing has become a focus area for enquiry as EDs worldwide look for ways to cope with over-crowding and reduce waiting times. In South African EDs, the target time for patients to be seen is dictated by their triage category. Pat...


More From BioPortfolio on "EXECU SUMMIT,LLC"

Advertisement
Quick Search
Advertisement
Advertisement